Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics
Introduction Brensocatib is an investigational, oral, reversible inhibitor of dipeptidyl peptidase-1 shown to prolong time to first exacerbation in adults with bronchiectasis. Outlined here are the clinical trial design, and baseline characteristics and treatment patterns of adult patients enrolled...
Na minha lista:
| Principais autores: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
European Respiratory Society
2024-07-01
|
| coleção: | ERJ Open Research |
| Acesso em linha: | http://openres.ersjournals.com/content/10/4/00151-2024.full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|